Skip to main content
Premium Trial:

Request an Annual Quote

Pangea Systems and Roche Bioscience Complete Chip Study

Premium

OAKLAND, Calif.--Pangea Systems completed its collaboration with Roche Bioscience for the design of expression chips from expressed sequence tagged databases. The system uses bioinformatics tools that will be available within Pangea's GeneWorld. The collaboration allowed the efficient design of DNA chips for gene families for therapeutic and diagnostic interest. Roche Senior Vice-President Robert Booth said, "With the help of Pangea's chip design software, we are able to detect previously unknown gene family members."

Pangea CEO John Couch said his firm's collaboration with Roche demonstrates the benefit of bringing information technology and biological research together to develop diagnostics and cures for diseases in less time.

Pangea's new software automatically segregates and classifies gene isoforms and polymorphisms that may be linked to disease so that chip designs are complete and of a high quality. Other components of the system provide validation and protection from artifacts such as chimerism and contamination inherent in EST data. The combined system allows the construction of chip design sets from incomplete, fragmented, and error-prone EST data and full-length sequences from both public and proprietary databases.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.